Literature DB >> 31896555

Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4+ T Cells.

Samuel J Hobbs1, Jake C Harbour1, Phillip A Yates2, Diana Ortiz1, Scott M Landfear1, Jeffrey C Nolz3,4,5.   

Abstract

CD4+ helper T cells play important roles in providing help to B cells, macrophages, and cytotoxic CD8+ T cells, but also exhibit direct effector functions against a variety of different pathogens. In contrast to CD8+ T cells, CD4+ T cells typically exhibit broader specificities and undergo less clonal expansion during many types of viral infections, which often makes the identification of virus-specific CD4+ T cells technically challenging. In this study, we have generated recombinant vaccinia virus (VacV) vectors that target I-Ab-restricted peptides for MHC class II (MHC-II) presentation to activate CD4+ T cells in mice. Conjugating the lymphocytic choriomeningitis virus immunodominant epitope GP61-80 to either LAMP1 to facilitate lysosomal targeting or to the MHC-II invariant chain (Ii) significantly increased the activation of Ag-specific CD4+ T cells in vivo. Immunization with VacV-Ii-GP61-80 activated endogenous Ag-specific CD4+ T cells that formed memory and rapidly re-expanded following heterologous challenge. Notably, immunization of mice with VacV expressing an MHC-II-restricted peptide from Leishmania species (PEPCK335-351) conjugated to either LAMP1 or Ii also generated Ag-specific memory CD4+ T cells that underwent robust secondary expansion following a visceral leishmaniasis infection, suggesting this approach could be used to generate Ag-specific memory CD4+ T cells against a variety of different pathogens. Overall, our data show that VacV vectors targeting peptides for MHC-II presentation is an effective strategy to activate Ag-specific CD4+ T cells in vivo and could be used to study Ag-specific effector and memory CD4+ T cell responses against a variety of viral, bacterial, or parasitic infections.
Copyright © 2020 The Authors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31896555      PMCID: PMC7380490          DOI: 10.4049/immunohorizons.1900070

Source DB:  PubMed          Journal:  Immunohorizons        ISSN: 2573-7732


  58 in total

1.  Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection.

Authors:  Min Fang; Nicholas A Siciliano; Adam R Hersperger; Felicia Roscoe; Angela Hu; Xueying Ma; Ahamed R Shamsedeen; Laurence C Eisenlohr; Luis J Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 2.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

3.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

4.  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

Authors:  Laila E Gamadia; Ester B M Remmerswaal; Jan F Weel; Frederieke Bemelman; René A W van Lier; Ineke J M Ten Berge
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

5.  HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome.

Authors:  Damien Z Soghoian; Heiko Jessen; Michael Flanders; Kailan Sierra-Davidson; Sam Cutler; Thomas Pertel; Srinika Ranasinghe; Madelene Lindqvist; Isaiah Davis; Kimberly Lane; Jenna Rychert; Eric S Rosenberg; Alicja Piechocka-Trocha; Abraham L Brass; Jason M Brenchley; Bruce D Walker; Hendrik Streeck
Journal:  Sci Transl Med       Date:  2012-02-29       Impact factor: 17.956

6.  CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting.

Authors:  F Rodriguez; S Harkins; J M Redwine; J M de Pereda; J L Whitton
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2.

Authors:  C A Scanga; V P Mohan; K Yu; H Joseph; K Tanaka; J Chan; J L Flynn
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

8.  Central memory CD8+ T cells become CD69+ tissue-residents during viral skin infection independent of CD62L-mediated lymph node surveillance.

Authors:  Jossef F Osborn; Samuel J Hobbs; Jana L Mooster; Tahsin N Khan; Augustus M Kilgore; Jake C Harbour; Jeffrey C Nolz
Journal:  PLoS Pathog       Date:  2019-03-15       Impact factor: 6.823

9.  Endogenous antigen processing drives the primary CD4+ T cell response to influenza.

Authors:  Michael A Miller; Asha Purnima V Ganesan; Nancy Luckashenak; Mark Mendonca; Laurence C Eisenlohr
Journal:  Nat Med       Date:  2015-09-28       Impact factor: 53.440

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  2 in total

1.  Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.

Authors:  Jake C Harbour; Zoe L Lyski; John B Schell; Archana Thomas; William B Messer; Mark K Slifka; Jeffrey C Nolz
Journal:  J Immunol       Date:  2021-05-10       Impact factor: 5.426

2.  Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs.

Authors:  Patrick Neckermann; Ditte Rahbaek Boilesen; Torsten Willert; Cordula Pertl; Silke Schrödel; Christian Thirion; Benedikt Asbach; Peter Johannes Holst; Ralf Wagner
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.